Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Jan 27, 2023 12:42pm
141 Views
Post# 35250431

RE:RE:RE:RE:RE:New asset opportunities

RE:RE:RE:RE:RE:New asset opportunitiesGiven developments, I'm fine with having all senior managers aligned to seeing shareholder returns for comp - in fact, I'd cut cash and give them more options even at this low price. I want a huge incentive to do whatever they can to claw there way back to $300mil+ valuation given revenues are projected for close to $100m and growing. 

I wouldn't count too much on the tuck-in sales talk. It's all fine, and makes even more sense now that they've brought it in-house and shown they are actually doing a solid job and trying to be innovative in their approach. The CCO from Pfizer has done well. But pharma companies with sales apparatus are always looking for products. They do have the advantage of focusing on a very specific subset.  What would be a nice surprise is if doctors voiceing a desire for the combo of trogarzo and that new Gilead drug help push that in to something that's incrementally very positive in the short term. 

SABBOBCAT wrote:

Any company I have been a part of does not decide on or grant bonuses until after the year ends, so the few days of timing should be irrelevant. However with that being said, they did switch thier option granting logic a while ago so I am curious. 

Considering that there were trial delays and other issues, it will be shocking if full bonuses are dolled out anywhere. 



SPCEO1 wrote: When the proxy comes out this year, the salary, options awards and bonus info is going to be interesting reading. Given the company's year-end was 11/30 and the TH-1902 trial pause came the next day, TH may have already committed to paying bonuses and salaries it may not have committed to if they knew the pause was going to happen ahead of time. Obviously, there is a lot of potential for shareholders to go ballistic when those numebrs come out. Hopefully, adjustments were able to be made for the top officers if salaries, bonuses and options grants granted pre-12/1 now look foolish and financially irresponsible. If not, or if they are unable to announce anything positive to lift the share price, then it is not hard to see that shareholders will be in a very bad mood.

Let's hope they produce some positive news on NASH or Th-1902 in the not too distant future.
Trogarzon wrote: And for the modest sum of 2M a year salary... in plain english... what has a new CEO acheived in the pas 36 months... and now we need Luc again.. so save the face of the company by managing leen.  



 



<< Previous
Bullboard Posts
Next >>